{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:17:17Z","timestamp":1787854637414,"version":"build-2784847793"},"reference-count":32,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2026,8,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the trial-based cost-effectiveness of an intravenous fosaprepitant-based antiemetic regimen compared with oral aprepitant, in combination with ondansetron and dexamethasone, among children receiving highly emetogenic chemotherapy in India and the USA using individual patient-level data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Costs were estimated from a private payer perspective in India and the USA. Health outcomes were expressed as quality-adjusted life-years (QALYs). Incremental cost-utility ratio (ICUR) and incremental net monetary benefit (iNMB) were calculated. Uncertainty was evaluated through one-way deterministic sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 140 and 139 children were enrolled in the fosaprepitant and aprepitant groups, respectively. Mean QALYs were marginally higher in the aprepitant group (0.0118 vs 0.0116; difference: 0.0002). In India, mean costs were $33.94 in the fosaprepitant arm vs $19.73 in the aprepitant arm (difference: $14.21). In the USA, mean costs were $615.92 vs $809.73, respectively, in the two arms (difference: $193.81), favouring fosaprepitant. iNMB values of fosaprepitant compared with aprepitant were \u2013$15.59 in India and $173.81 in the USA, indicating lack of cost-effectiveness for fosaprepitant in India but cost-effectiveness in the USA. In sensitivity analyses, the ICUR was most sensitive to the cost of fosaprepitant in India and to the utility value of the complete protection health state in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravenous fosaprepitant, administered in combination with ondansetron and dexamethasone, was not cost-effective compared with oral aprepitant-based combination therapy in India but demonstrated cost-effectiveness in the USA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2026-006355","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:20:29Z","timestamp":1787851229000},"page":"spcare-2026-006355","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial"],"prefix":"10.1136","author":[{"given":"Rahul","family":"Kumar","sequence":"first","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manraj Singh","family":"Sra","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic Minnesota, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azgar Abdul","family":"Rasheed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, KIMS Cancer Centre, Trivandrum, Kerla, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sasi","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-6088","authenticated-orcid":false,"given":"Shuvadeep","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"},{"name":"Medical Oncology, All India Institute of Medical Sciences Kalyani, Kalyani, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Medical Oncology, All India Institute of Medical Sciences New Delhi, New Delhi, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082710201693000_spcare-2026-006355v1.1","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"2026082710201693000_spcare-2026-006355v1.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21631"},{"key":"2026082710201693000_spcare-2026-006355v1.3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.2017.35.31_suppl.155","article-title":"Hospitalization costs for nausea and vomiting: A savings opportunity","volume":"35","author":"Roeland","year":"2017","journal-title":"JCO"},{"key":"2026082710201693000_spcare-2026-006355v1.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2714-9"},{"key":"2026082710201693000_spcare-2026-006355v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"2026082710201693000_spcare-2026-006355v1.6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30001","article-title":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline","volume":"69","author":"Patel","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026082710201693000_spcare-2026-006355v1.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"2026082710201693000_spcare-2026-006355v1.8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ped.13780","article-title":"Evaluation of aprepitant and fosaprepitant in pediatric patients","volume":"61","author":"Saito","year":"2019","journal-title":"Pediatrics International"},{"key":"2026082710201693000_spcare-2026-006355v1.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002595"},{"key":"2026082710201693000_spcare-2026-006355v1.10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29795","article-title":"Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial","volume":"69","author":"Sra","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026082710201693000_spcare-2026-006355v1.11","doi-asserted-by":"crossref","DOI":"10.1002\/1545-5017.70171","article-title":"Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator-Initiated Randomized, Open-Label, Non-Inferiority Trial","volume":"73","author":"Rasheed","year":"2026","journal-title":"Pediatr Blood Cancer"},{"key":"2026082710201693000_spcare-2026-006355v1.12","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050616","article-title":"Anti-Emetics in Children Receiving Chemotherapy for Solid Tumors and Leukemia: Pharmacology and Optimization of Therapy for Nausea and Vomiting","volume":"17","author":"Ganguly","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026082710201693000_spcare-2026-006355v1.13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.mjafi.2013.06.003","article-title":"Health economics and cost-effectiveness research with special reference to hemato-oncology","volume":"69","author":"Kumar","year":"2013","journal-title":"Med J Armed Forces India"},{"key":"2026082710201693000_spcare-2026-006355v1.14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.clinthera.2019.03.011","article-title":"Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan","volume":"41","author":"Kashiwa","year":"2019","journal-title":"Clin Ther"},{"key":"2026082710201693000_spcare-2026-006355v1.15","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-018-0073-z","article-title":"Cost-effectiveness of health care service delivery interventions in low and middle income countries: a systematic review","volume":"3","author":"Watson","year":"2018","journal-title":"Glob Health Res Policy"},{"key":"2026082710201693000_spcare-2026-006355v1.16","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27690","article-title":"Pharmacokinetics\/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"66","author":"Mora","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2026082710201693000_spcare-2026-006355v1.17","unstructured":"European Medicines Agency (EMA) . Ivemend, 2018. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ivemend [Accessed 24 May 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.18","unstructured":"1mg . Online Pharmacy India | Buy Medicines from India\u2019s Trusted Medicine Store, Available: https:\/\/www.1mg.com [Accessed 21 Mar 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.19","unstructured":"IndiaMART . IndiaMART - Indian Manufacturers Suppliers Exporters Directory,India Exporter Manufacturer, Available: https:\/\/www.indiamart.com [Accessed 21 Mar 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.20","doi-asserted-by":"publisher","DOI":"10.1136\/spcare-2022-004069"},{"key":"2026082710201693000_spcare-2026-006355v1.21","unstructured":"Veterans Affairs . Logistics O of P Acquisition and. VA.gov, Available: https:\/\/www.va.gov\/opal\/nac\/fss\/pharmPrices.asp [Accessed 27 Apr 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.22","unstructured":"USA Medical and Surgical Supply Store . Medical Supply Store, Available: https:\/\/www.usamedicalsurgical.com\/?srsltid=AfmBOorUUUFtj5eCxn-9-jaXHtW1CwIdLGfItt2Dp62Xgiq2vwKJ_owZ [Accessed 21 Mar 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.23","unstructured":"DrugsCom . Drugs.com \u2013 know more. be sure. Available: https:\/\/www.drugs.com\/ [Accessed 21 Mar 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.24","unstructured":"Healthcare Cost and Utilization Project (HCUP), Available: https:\/\/www.ahrq.gov\/data\/hcup\/index.html [Accessed 21 Mar 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.25","unstructured":"Nationwide Children\u2019s Hospital Price Information, Available: https:\/\/www.nationwidechildrens.org\/your-visit\/billing-and-insurance\/pay-my-bill\/price-information-list [Accessed 27 Apr 2026]."},{"key":"2026082710201693000_spcare-2026-006355v1.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0710-6"},{"key":"2026082710201693000_spcare-2026-006355v1.27","unstructured":"Edejer, Tessa Tan-Torres, and World Health Organization . Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003."},{"key":"2026082710201693000_spcare-2026-006355v1.28","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1392"},{"key":"2026082710201693000_spcare-2026-006355v1.29","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27551","article-title":"Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial","volume":"66","author":"Radhakrishnan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2026082710201693000_spcare-2026-006355v1.30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08880018.2024.2437047","article-title":"Safety and Tolerability of a 3-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients: Results of an Open-Label, Single-Arm Phase 4 Trial","volume":"42","author":"Garcia Leon","year":"2025","journal-title":"Pediatr Hematol Oncol"},{"key":"2026082710201693000_spcare-2026-006355v1.31","unstructured":"EMEND (fosaprepitant) for injection, for intravenous use Initial U.S. Approval. 2008."},{"key":"2026082710201693000_spcare-2026-006355v1.32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00432-024-05766-7","article-title":"Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2026-006355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:20:32Z","timestamp":1787851232000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2026-006355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":32,"alternative-id":["10.1136\/spcare-2026-006355"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2026-006355","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}